Fourteen patients with EGFR-mutant and RET fusion-positive lung cancers who experienced prior progression on osimertinib received osimertinib and selpercatinib….The response rate, disease control rate, and median treatment duration were 50% (95%CI 25%-75%, n=12), 83% (95%CI 55%-95%%), and 7.9 months (range 0.8-25+), respectively....For patients with EGFR-mutant NSCLC with an acquired RET fusion as a mechanism of EGFR inhibitor resistance, the addition of selpercatinib to osimertinib was feasible, safe, and offered clinical benefit, supporting the prospective evaluation of this combination.